Kador, Ph.D.
`
`1
`
`Curriculum Vitae
`
`Peter Fritz Kador, Ph.D.
`Professor Department of Pharmaceutical Sciences
`College of Pharmacy
`986025 Nebraska Medical Center
`Omaha, NE 68198-6025
`
`pkador@unmc.edu
`
`United States
`
`
`Citizenship:
`
`Education:
`1968-1972
`1972-1976
`
`
`
`
`
`B.A. (Chemistry) Capital University, Columbus, OH
`Ph.D. (Medicinal Chemistry) Ohio State University, Columbus, OH
`(Thesis: "Selected tetrahydroisoquinoline analogs and their fragmented derivatives as beta-
`adrenergic agonists" Advisor Prof. Duane D. Miller)
`
`Brief Chronology of Employment:
`
` Summers 1967-69 Laboratory technician, Ohio State University Bee Laboratory
` Summer 1970
`Laboratory technician, Ohio State University, Department of Physiological Chemistry
` Summers 1971-72 Chemical Abstract Service, Selection and Assignment Section, American Chemical Society,
`Columbus, OH
`Laboratory Instructor, Freshman Chemistry, Capital University, Columbus, OH
`Recitation Teaching Assistant, Medicinal Chemistry, Ohio State University College of
`Pharmacy
`Tutor, Ohio State University College of Pharmacy
`Staff Fellow, Laboratory of Vision Research, National Eye Institute, National Institutes of
`Health, Bethesda, MD, Advisor Jin H. Kinoshita, Ph.D.
`Research Chemist, GS 13, Laboratory of Vision Research, National Eye Institute, National
`Institutes of Health, Bethesda, MD
`Research Chemist, GS 14, Laboratory of Vision Research, National Eye Institute, National
`Institutes of Health, Bethesda, MD.
`Head, Section of Molecular Pharmacology, Laboratory of Mechanisms of Ocular Disease,
`National Eye Institute, National Institutes of Health, Bethesda, MD
`Research Chemist, GS 15, Molecular Pharmacology Section, Laboratory of Mechanisms of
`Ocular Disease, National Eye Institute, National Institutes of Health, Bethesda, MD.
`Chief, Laboratory of Ocular Therapeutics, National Eye Institute, National Institutes of Health
`Professor and Chair, Department of Pharmaceutical Sciences, College of Pharmacy, University
`of Nebraska Medical Center, Omaha, NE
`Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of
`Nebraska Medical Center, Omaha, NE
`
`
`
`
`1971-1972
`1972-1973
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1973-1976
`1976-1979
`
`1979-1983
`
`1983-1985
`
`1985-1989
`
`1989-1991
`
`1991-2002
`2002-2003
`
`2003-present
`
`
`Other Appointments
`
`1999 – 2002
`Courtesy Professor, Department of Veterinary and Biomedical Sciences, University of
`Nebraska, Lincoln, NE
`Adjunct Professor, School of Veterinary Medicine and Biomedical Sciences, University of
`Nebraska, Lincoln, NE
`Adjunct Professor, Department Ophthalmology, College of Medicine, University of Nebraska
`Medical Center, Omaha, NE
`
`2003 – Present
`
`2003 – Present
`
`FAMY CARE - EXHIBIT 1032-0001
`
`

`
`Kador, Ph.D.
`
`2003 – 2006
`
`2004- Present
`2010-2015
`
`Adjunct Professor, Department of Pharmacology and Neurosciences, College of Medicine,
`University of Nebraska Medical Center, Omaha, NE
`President and C.E.O. Therapeutic Vision, Inc., Omaha, NE.
`Guest Professor, Department of Ophthalmology, Xijing Hospital, Fourth Military Medical
`University, Xi’an, People’s Republic of China.
`
`2
`
`
`Research Interests
`
`
`
`•
`
`• Diabetic complications, retinopathies, cataract development, neurodegeneration, macular degeneration
`• Design and synthesis of multifunctional antioxidants and enzyme inhibitors
`• Mechanism of action of neuroprotective drugs and for the treatment of age related degenerative diseases
`in the eye and neural tissues
`• Development of animal models for ophthalmic complications
`• Translational studies for applying drugs to the veterinary companion pet market.
`• Development of ophthalmic nutraceuticals.
`
`Major Accomplishments
`
`
` Drug Development
`• Synthesized new class of multifunctional antioxidants that possess a novel 2-amino-4-hydroxylpyrimidine
`ring system. These are orally active compounds that demonstrate selective chelation of transition metals
`associated with Fenton’s reaction and possess free radical scavenger activity. Preliminary studies indicate
`that they are good candidates for the treatment of cataract, macular degeneration, and Alzheimer’s and
`Parkinson’s disease.
`• Developed the topical formulation KinostatTM and demonstrated clinical efficacy of this drug for the
`prevention of cataracts in diabetic dogs. Obtained SBIR Phase 1 and 2 funding and FDA MUMS
`designation for commercial development.
`Invented topical nutraceutical Optixcare EH for the reduction of ocular oxidative stress and treatment of
`dry eye.
`
` Lens Studies
`• Expert on conducting in vitro lens culture studies using rat, rabbit, dog and human lenses to elucidate the
`cataractogenic mechanism of select drugs.
`• Discovered a choline transport system in the lens that is a sensitive measure of lens biochemical viability.
`• Demonstrated sugar cataracts in dogs are osmotic in nature, and that these cataracts can be inhibited by
`aldose reductase inhibitors.
`• Demonstrated the feasibility of utilizing MTC-MRI to investigate osmotic changes in human sugar
`cataracts.
`• Demonstrated that altered redox changes associated with sorbitol dehydrogenase inhibitors, and non-
`enzymatic glycosylation and advanced glycosylation endproducts (AGEs) form sugar cataracts that are
`secondary to aldose reductase initiated cataract formation.
`• Discovered that a group of compounds derived from a known sorbitol dehydrogenase inhibitor delay
`advanced sugar cataracts through a mechanism independent of the polyol pathway.
`• Synthesized novel multifunctional antioxidants and demonstrated that they accumulate in the lens and
`retina and delay cataract formation.
`
`
`Enzyme Studies
`• Purified and characterized aldose reductase from human placenta, rat, and dog lenses. Developed
`antibodies against these enzymes and then localized the enzyme in various tissues by immuno-
`histochemistry.
`
`FAMY CARE - EXHIBIT 1032-0002
`
`

`
`Kador, Ph.D.
`
`3
`
`
`
`
`
`
`
`• Purified and characterized aldehyde reductase in rat and dog lenses.
`• Purified and characterized a separate NADPH-dependent reductase not related to aldose or aldehyde
`reductase in dog thyroid.
`• Confirmed that the production of sorbitol, galactitol and xylitol is enzymatic in nature and not due to
`“auto-oxidation”.
`• Defined flux changes in the metabolism of glucose by aldose reductase, sorbitol dehydrogenase and
`glucose, galactose and xylose oxidase in tissues and cells associated with diabetic complications.
`Aldose Reductase Inhibitors
`• Defined mechanisms of action and pharmacophore requirements of aldose reductase inhibitors.
`• Demonstrated feasibility of utilizing affinity labeled analogs of aldose reductase inhibitors to identify
`reactive regions on the enzyme.
`• Using affinity labels, demonstrated the feasibility of an alternate inhibitor site on the enzyme.
`• Using molecular modeling and quantum mechanical calculations, defined binding and potential
`mechanism of action of inhibitors in the substrate binding site.
`• Defined differences in the susceptibility to inhibition of aldose reductase inhibitors with aldose versus
`aldehyde reductase.
`• Discovered an intrinsic inhibitor of aldose reductase in mammalian tissues.
`
`
`Retina
`• Defined the progression of retinal lesions in the galactose-fed dog model and demonstrated that it begins
`with the selective degeneration of retinal capillary pericytes.
`• Developed computer assisted method for quantifying retinal capillary changes and demonstrated that
`inhibition of aldose reductase in the early stages can arrest the development of retinal lesions.
`• Demonstrated aldose reductase inhibitors prevent the onset of retinopathy in a dose-dependent manner
`and demonstrated that removal of galactose diet (equivalent to inhibition of aldose reductase) at the early
`stages of retinopathy where pericyte ghosts and microaneurysms occur also prevents the further
`progression of retinopathy.
`• Demonstrated that aldose reductase inhibitors can inhibit capillary basement membrane thickening
`associated with diabetes.
`• Demonstrated that retinal capillaries with thickened basement membranes do not increase in permeability
`as commonly believed.
`Other Ocular Tissues:
`• Demonstrated that corneal epithelium and endothelium changes are associated with aldose reductase in
`the rat and dog, respectively.
`• Demonstrated that aldose reductase inhibitors prevent delayed pupil dilation changes associated with
`neuropathy and histological changes of the iris that results in fibrosis.
`• Demonstrated that galactose-fed dogs undergo autoimmune thyroid changes similar to those clinically
`observed in diabetics and that these are linked to aldose reductase.
`• Determined structure of asteroid hyalosis in vitreous
`Animal Models:
`• Developed two strains of a Philly mouse cataract model, one that developed early hereditary cataracts at
`approximately 3 weeks and one that developed hereditary cataracts at approximately 8 weeks after birth.
`• Refined and extensively investigated the galactose-fed dog model. Demonstrated that this dog develops
`retinal lesions that are clinically and histochemically similar to human diabetic retinopathy from the
`background stage of dot and blot microaneurysms to the proliferative end stage. Also demonstrated that
`the dog develops the ocular changes of iris vessel leakage, cataract, keratopathy and asteroid hyalosis. In
`addition, demonstrated that neuropathy and nephropathy does not develop in galactose-fed dogs while
`
`FAMY CARE - EXHIBIT 1032-0003
`
`

`
`Kador, Ph.D.
`
`4
`
`
`
`nephropathy and cardiac myopathy does develop in the latter stages.
`• Developed a mouse models that contains green fluorescent protein and human aldose reductase in
`vascular cells containing smooth muscles, including retinal capillary pericytes.
`• Developed natural diabetic mouse models that containing green fluorescent protein and human aldose
`reductase in vascular cells containing smooth muscles, including retinal capillary pericytes.
`Other Tissues:
`• Demonstrated that aldose reductase inhibitors prevent alveolar bone loss in periodontal disease.
`In diabetic rats, verified that motor nerve conduction is normalized by a number of aldose reductase
`•
`inhibitors and demonstrated that MNC reduction was directly linked to sorbitol formation.
`• Demonstrated that both diabetic and galactosemic rats produced proteinuria that can be prevented by
`aldose reductase inhibitors. Also demonstrated that aldehyde reductase rather than aldose reductase was
`primarily involved in proteinuria.
`• Demonstrated that unlike man or rat, neuropathy is absent in galactose-fed dogs. MNC remains normal
`despite that fact that galactitol levels are elevated, myoinositol levels are decreased and the
`lactate/pyruvate levels, indicative of redox changes are abnormal. Moreover, no morphological changes
`occur in the dog nerve, suggesting that an unknown preventative factor is present in dog nerve.
`• Demonstrated that aldose reductase was involved in norepinephrine metabolism.
`
`
`
`
`Professional Societies:
`American Chemical Society
`Medicinal Chemical Division, American Chemical Society
`Association for Ocular Pharmacology and Therapeutics
`Association for Research in Vision and Ophthalmology
`American Association of Pharmaceutical Scientists
`American Diabetes Association
`European Association for the Study of Diabetes
`European Vision and Eye Research
`International Diabetes Federation
`International Society for Eye Research
`Sigma Xi Research Society
`European Vision and Eye Research
`United Health Coucil
`
`Awards Received
`
`Vision Research Related (chronological)
`
`Rohto Foundation Cataract Research Award, recipient, May, 1981
`Foundation for the Advancement of Science Fellow sponsored by Ayerst Research Laboratories, Inc., 1983-1984;
`1984-1985.
`Alcon Foundation Research Award, recipient April, 1986
`Juvenile Diabetes Foundation Research Award, 1986
`Juvenile Diabetes Foundation Research Award, 1987
`Kinoshita Lectureship, National Foundation for Eye Research, Kona, Hawaii, November, 1995.
` Foundation for the Advancement of Science Research Award sponsored by Pfizer Pharmaceuticals, 1998.
` Fellow, American Association of Pharmaceutical Scientists, November 2004
`
`Japanese Cataract Cooperative Research Group Award, November 2005
` Fellow, Association for Research in Vision and Ophthalmology, 2010
` Distinguished Scientist, University of Nebraska Medical Center, 2010
` Ernst H. Bárány Prize, International Society of Eye Research, Berlin, Germany, 2012.
`
`
`FAMY CARE - EXHIBIT 1032-0004
`
`

`
`Kador, Ph.D.
`
`5
`
`Other (chronological)
`
`Columbus Technical Council Science Student of the Year, 1968
`International Science Fair, Detroit MI, Fourth Award, 1968
`Ford-Future Scientists of America Regional Award, 1968
`Central Ohio Heart Association Undergraduate Research Scholarship
`"Effect of Various Honeybee Extracts on Black Bee Disease", 1970-71
`Central Ohio Heart Association Undergraduate Research Scholarship
`"O-Alkyldiglyceride Analysis in Rat Adipose Tissue", 1971-72
`National Institutes of Health Pre-doctoral Trainee in Medicinal Chemistry, 1972-76
`Alumni Achievement Award of Capital University, May 1990
`Jack Beal Postbaccalaureate Alumni Achievement Award, Ohio State University College of
`
`Pharmacy, Columbus, Ohio, May, 1992
`Bundesverdienstkreuz (Federal Cross of Merit) from the German Government, German Embassy,
`Washington, DC. November, 1994
`
`Other Professional Activities
`
`Executive Vice-President of the National Foundation for Eye Research, January, 1996 - present.
`Trustee of the Association for Ocular Pharmacology and Therapeutics (AOPT), 1995 – 2001; 2011-present
`President of Ocular Pharmacology and Therapeutics (AOPT), 2004-2011.
`Member, U.S. Cataract Cooperative Research Group Planning Board, 1994 - present
` Consultant on cataract drug development, Shojin Research Associates, Studio City, CA 1990-2001
`Expert Committee Member, US Pharmacopeia, 2000-2006
`Consultant on ocular toxicology, Merck & Co., Inc. 2001- 2006
`Consultant, MedVet Columbus 2007-2008.
`Consultant on ocular toxicology, Eli Lilly and Company 2007-2009.
`Consultant on ocular toxicology, Johnson and Johnson Company 2009-2010.
`Scientific Advisory Board, Encore Vision 2007-2010.
`Scientific Advisor, Aventix Animal Health 2010-present
`Scientific Advisory Board, Merz Pharmaceuticals GmbH 2011-2012.
`Consultant and Expert Witness, Rakoczy Molino Mazzochi Siwik LLP Patent Attorneys 2012-present.
`Consultant, IPExperts, LLC, 2014- present
`Consultant on ocular toxicology, Vertex Pharmaceutical Company 2014-2015
`Consultant and Expert Witness, Covington and Burling LLP 2016-present.
`
`Continuing Education Courses
`
` Conducting Clinical Trials, National Eye Institute, 1984
` Using Molecular Biology for Drug Discovery; American Chemical Society, 2001
` Bioinformatics, Rensselaer Polytechnical Institute, 2000
` Managing Government Employees, Brookings Institute 1998
`
`Requested Editing
`
`Editorial Board Member, Journal Ocular Pharmacology and Therapeutics, 1997 – 2000; 2008 - current
`Co-editor Polyol Pathway and its Role in Diabetic Complications, Excerpta Medica, International
`Congress Series 760
`Co-editor Current Concepts of Aldose Reductase and its Inhibitors Excerpta Medica, International
`Congress Series 913
`
`Journal Reviews
`
`American Journal of Physiology, Biochemical Pharmacology, Bioorganic and Medicinal Chemistry,
`
`FAMY CARE - EXHIBIT 1032-0005
`
`

`
`Kador, Ph.D.
`
`6
`
`Diabetologia, Endocrinology, Journal of Diabetes and its Complications, Current Eye Research, European Journal
`of Physiology, Experimental Eye Research, Investigative Ophthalmology and Visual Sciences, Journal of Clinical
`Investigation, Journal of Medicinal Chemistry, Journal European Medicinal Chemistry, Journal Ocular
`Pharmacology and Therapeutics, Ophthalmologia, British J. Ophthalmology, Vision Research, Expert Opinion on
`Drugs, Toxicology.
`
`Grant Reviews
`
`NIH Study Sections Visual C (1991), Diabetic Complications (1995-1998); Environmental Health (2008); NIST
`grants (1996); Veterans Administration (1998); Consultant, FDA Federal Drug Administration, 1987. Welcomb
`Trust 1998, 1999
`
`Committee Memberships
`
`N.I.H. Advisory Committee of Computer Users, 1982-86; 1988-1991.
`Central Facilities Advisory Committee to Veterinary Resources Program, NCRR 1993-1998
`In Vivo NMR Center Steering Committee, 1994- 2002
`N.E.I. Promotions Committee 1990 - 2002
`N.E.I. Animal Care and Use Committee, 1997 - 2002.
` UNMC College of Pharmacy Executive Committee 2002-2003
` UNMC College of Pharmacy Educational Technology Committee 2002-
` UNMC College of Pharmacy Strategic Planning Committee 2002-2003
` UNMC College of Pharmacy Faculty Development Committee 2002-2003
` UNMC College of Pharmacy Educational Technology Committee 2003-2004
` UNMC College of Pharmacy Recruitment Committee 2003-2005
` UNMC College of Pharmacy Student Discipline 2005-2006
` UNMC College of Pharmacy Research Faculty Appointment 2005-2009
`UNMC College of Pharmacy Grade Appeals 2007-2014
`UNMC College of Pharmacy Curriculum Committee 2008-present
`UNMC College of Pharmacy Faculty Development 2015- present
`UNMC College of Pharmacy Rho Chi Faculty Advisor 2014 present
`
`
`
`Meetings Chaired or Organized
`
`Chairman, NEI Aldose Reductase Workshop, Bethesda, MD, March, 1982.
`Chairman, US-Japan Aldose Reductase Workshop, Honolulu, Hawaii, December, 1984.
`Scientific Secretary, International Symposium on Polyol Pathway and its Role in Diabetic Complications,
`Kashikojima, Japan, October, 1986.
`Chairman, International Aldose Reductase Workshop, Honolulu, Hawaii, December, 1987.
`Co-Organizer, University of München Augenklinik - National Eye Institute Aldose Reductase Inhibitor
` Workshop, Munich, Germany, October, 1988.
`Co-Organizer, Japan-US Aldose Reductase Workshop, Nagoya, Japan, November. 1989.
`Co-Organizer, United States-Japan Aldose Reductase Workshop, Kona, Hawaii, February, 1991.
`Co-Organizer, International Cataract Cooperative Research Group Workshop, Bethesda, MD November, 1993.
`Co-Organizer, United States-Japan Aldose Reductase Workshop, Kona, Hawaii, February, 1994.
`Co-Organizer, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii, Nov., 1995.
`Co-Organizer, United States-Japan Aldose Reductase Workshop, Kona, Hawaii, February, 1997.
`Organizer, 3rd Annual Ocular Pharmacology and Therapeutics Meeting, Bethesda, MD October, 1997.
`Co-Organizer, Venkat Reddy International Symposium, Warrenton, VA, October 1998.
`Co-Organizer, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii, November,
`1999.
`Co-Organizer, United States-Japan Aldose Reductase Workshop, Kona, Hawaii, January, 2000.
`Co-Organizer, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii, Nov. 2001.
`
`FAMY CARE - EXHIBIT 1032-0006
`
`

`
`Kador, Ph.D.
`
`7
`
`Co-Organizer and Chair, Association for Ocular Pharmacology and Therapeutics, Kona, Hawaii, February 2003.
`Organizer and Chair, Abraham Spector International Symposium, Montauk, NY October 2003.
`Co-Organizer, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii,
` February, 2004.
`Co-Organizer, International Polyol Pathway Conference, Kona, Hawaii, March, 2004.
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, Catania, Italy, February 2005.
`Organizing Committee, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii,
`October, 2005.
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, San Diego, CA February 2007.
`Co-Organizer, and Co-Chairmen, Diabetes Complications 2007: Role of Aldose Reductase and Related Pathways.
`Kona, Hawaii, March, 2007.
`Organizing Committee, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii,
`December 2007.
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, Salzburg, Austria, February
`2009.
`Organizing Committee, United States-Japan Cataract Cooperative Research Group Meeting, Kona, Hawaii,
`December 2009
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, Ft. Worth, TX, February 2011
`Organizing Committee, International Conference on the Lens, Kona, Hawaii, January 2011
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, Alicante, Spain, February 2013
`Organizing Committee, International Conference on the Lens, Kona, Hawaii, January 2014
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, Charleston, SC, March 2015
`Organizing Committee, International Conference on the Lens, Kona, Hawaii, December 2015
`Organizing Committee, Association for Ocular Pharmacology and Therapeutics, Florence Italy, February 2017
`
`
`
`
`
`Invited Lectures
`Ocular Pharmacology Update, Irvine, CA, October, 1982
`American Chemical Society Division of Medicinal Chemistry National Meeting, Washington D.C.,
`August 1983
`Ciba Foundation Symposium 106 on Human Cataract Formation, London, England, October, 1983
`Gordon Research Conference on Medicinal Chemistry, New London, NH, July, 1984
`American Chemical Society Division of Medicinal Chemistry National Meeting, Philadelphia, PA,
` August. 1984
`National Eye Institute Symposium on Experimental Eye Pathology, February, 1985.
`Pfizer Aldose Reductase Symposium, Dorado, Puerto Rico, May, 1985.
`American Diabetes Society Aldose Reductase Workshop, Baltimore, MD, June, 1985.
`Centennial Speaker, the Ohio State University College of Pharmacy, May, 1986.
`Helen Keller International-National Eye Institute Meeting to Develop Worldwide Plan
`for Cataract Intervention, Bethesda, MD, June, 1986.
`Ninth National Research To Prevent Blindness Science Writers Seminar in Ophthalmology,
` Bethesda, MD, October, 1986.
`Tohoku Medical Society, Sendai, Japan, November, 1986.
`Interdisciplinary meeting on Diabetic Retinopathy, Florence, Italy, September, 1987.
`Juvenile Diabetes Foundation International Second World Congress on Diabetes Research,
`Monaco, Monte Carlo, March, 1988.
`Third International Symposium on Diabetes Mellitus, Nagoya, Japan, July, 1988.
`Thirteenth International Diabetes Federation Congress, Sydney, Australia, November, 1988.
`1989 Plenary Session of the Medical Advisory Council (MEDAC) of Merck Sharp and Dohme,
`Copenhagen, Denmark, September, 1989.
`
`FAMY CARE - EXHIBIT 1032-0007
`
`

`
`Kador, Ph.D.
`
`8
`
`US-China Cataract Cooperative Research Workshop, Beijing, China, May, 1990.
`Ninth International Congress of Eye Research, Helsinki, Finland, July, 1990.
`Ukrainian Kiev Institute of Endocrinology and Metabolism, August, 1990.
`National Eye Institute - Juvenile Diabetes Foundation Aldose Reductase Workshop, Bethesda, MD,
`
`September, 1990.
`Moderator, 25th International Research Symposium of the American Diabetes Association, Woods
`Hole, MA, September, 1990.
`General Assembly of the International Federation of Pharmaceutical Manufacturers Associations,
`London, England, September, 1990.
`Fourteenth International Diabetes Federation Congress, Washington D.C. June, 1991.
`International Congress on Current Therapy and Research in Diabetic Eye Disease, Nijmegen, the Netherlands,
`September, 1991.
`Sixth Congress of the U.S.-Japan Cooperative Cataract Research Group Congress, Kona, Hawaii,
` November 20-December 5, 1991.
`German Diabetes Society Congress, Hannover, Germany, May, 1992.
`Seventy-fourth Annual Endocrine Society Meeting, San Antonio, Texas, June, 1992.
`Symposium on Imaging in Ophthalmology, University of Texas Health Science Center at San Antonio,
`
`San Antonio, Texas, June, 1992.
`William Harvey Research Conference on Diabetic Complications as Drug Targets, London, U.K., March, 1993.
`Research to Prevent Blindness Science Writers' Seminar, Studio City, CA, April, 1993.
`Disease Prevention Research at NIH: An Agenda for All, Bethesda, MD, October, 1993.
`International Diabetes Federation, Kobe, Japan, November, 1994.
`Kinki University, Osaka, Japan, November, 1994.
`Kinki Branch of the Pharmaceutical Society of Japan, Osaka University, Osaka, Japan, November, 1994.
`Japanese Ministry of Education Lectureship, Osaka University, Osaka, Japan, November, 1994.
`International Forum on Advanced Techniques in Lens and Cataract Research, Kanazawa, Japan, June, 1995.
`Korean Ophthalmological Society Meeting, Seoul, Korea, October, 1996.
`Research to Prevent Blindness Cataract Symposium, Washington, D.C., April, 1997.
`Japanese Society for Cataract Research 36th Meeting, Yokohama, Japan, June, 1997.
`Second Asian Cataract Research Conference, Pusan, Korea, June 1998.
`
`28th International Congress of Ophthalmology, Amsterdam, The Netherlands, June, 1998.
`25th Japanese Society for Crystalline Lens Research, Fukui, Japan, January, 1999.
`23rd International Conference of the Great Lakes College of Clinical Medicine, Baltimore, MD, September, 1999.
`Diabetic Complications 2000. Yokohama, Japan, February, 2000.
`International Society for Eye Research Meeting, October, 2000.
`5th Diabetic Neuropathy Satellite Conference, San Jose, Costa Rica, November, 2000.
`Conference on Developments for Retinal Diseases and Glaucoma, Knowledge Foundation, San Francisco, CA,
`March 2001.
`American Diabetes Association, National Meeting, June, 2003.
`6th Asian Cataract Research Conference, Beijing China, June 2006.
`International Society of Eye Research, Buenos Aires, Argentina, November 2006
`Pennington Scientific Symposium on Diabetic Complications, Baton Rouge, LA, January 29-30, 2007
`13th Conference of Japanese Society of Ophthalmic Diabetology Kyoto, Japan March 2007
`37th Cambridge Ophthalmological Symposium on the Vitreous. St John’s College, Cambridge, UK, September,
`2007.
`International Society for Eye Research, Beijing, China, September 2008.
`Ehrlich II – 2nd World Conference on Magic Bullets, Nürnberg, Germany October 2008.
`Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University, Xi’an, People’s Republic of
`China. June 2010.
`American Chemical Society Annual Meeting, Boston, MA, August 2010.
`University of Miami Bascom Palmer Eye Institute Resident Research Day, June 2012
`
`FAMY CARE - EXHIBIT 1032-0008
`
`

`
`Kador, Ph.D.
`
`9
`
`International Society for Eye Research, Berlin, Germany, July 2012.
`13th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ, September, 2012.
`Retina International Scientific and Medical Advisory Board Meeting, Seattle, Washington May, 2013.
`Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland June, 2013.
`UC Berkeley School of Optometry, Berkeley, California, April, 2014
`13th Congress of International Society for Ocular Toxicology, Kanazawa, Japan, October, 2014.
`University of Rostock, Rostock Germany July 2015.
`SUNY Buffalo, March 2016.
`
`Additional Research Funding: (Not from NEI Intramural Funds)
`
`Ayerst Research Laboratories, Inc., (1983-1984; 1984-1985). 2 post-doctoral fellows
`Juvenile Diabetes Foundation Research Award, (1986) post-doctoral fellow
`Juvenile Diabetes Foundation Research Award, (1987) post-doctoral fellow
`Juvenile Diabetes Foundation – NEI Research Award, 1991-92 $50,000
`Fujisawa Pharmaceutical Company – NEI Collaborative Agreement (1990-1993) evaluate an aldose reductase
`inhibitor on retinopathy $300,000.
`Pfizer Pharmaceutical Company for evaluation of the role of sorbitol dehydrogenase in diabetic complications
`(1998) $30,000.
`Material Collaborative Research Agreement with Oxigene 2001 ($88,000) for the evaluation of the anticancer
`agent Combretastatin A-4 prodrug (CA4P) on retinal neovascularization
`NEI Intramural Laboratory of Ocular Therapeutics Funding for FY2000-2001 was $1,554,856 including labor and
`benefits.
`
`Academic Funding
`
`1. Biochemical Evaluation of Lens Metabolism Contract with Merck Pharmaceutical Company 2002-2003 Kador
`(PI).
`
`
`2. Pharmacological Approaches to Treat Diabetic Retinopathy NIH R01 2003 – 2006 Direct Cost $525,000 Total
`Kompella (PI), Kador Co-Investigator
`
`
`3. Multifunctional Antioxidants as Anti-Cataract Agents NIH 1R21EY016460-01 2006-2008 Direct Costs $
`250,000 Kador (PI)
`
`
`4.
`
`Investigating the Molecular Mechanism of Hexose-induced Stress in Lens and Retina 1R01EY016730-01
`NIH/NEI Kador (PI), Shinohara (Co-PI) 2006-2011
`
`
`5. Treatment for Canine Diabetic Cataracts Agency: Therapeutic Vision Inc. Subcontract of SBIR Grant
`1R43EY018013-01A1 9/1/07-8/31/08 Wyman (PI)
`
`
`6. Evaluation of Fidarestat for the Treatment of Periodontal Disease Agency: Therapeutic Vision Inc. Contract
`with Sanwa Pharmaceutical Company 1/2/2008.
`
`
`7. Treatment of Diabetic Periodontal Disease American Diabetes Society. 1-09-RA-82 2/15/2009 - 2/14/2012
`Kador (PI) 7/2009 – 6/30/2011.
`
`
`8. Evaluating the mechanism of cataract formation in the rat and dog lens. Agency: Therapeutic Vision Inc.
`Contract with Johnson and Johnson Pharmaceutical Company 1/2/2010.
`
`
`9. Treatment of Canine Diabetic Cataracts, Therapeutic Vision Inc. 2 R44 EY018013-02A1 9/17/2010 – 9/16/2013
`Direct Costs $ 1,222,560. Wyman (PI) Subcontract to Kador.
`
`
`10. Orally Active Bioavailable Metal Attenuating Compounds for Alzheimer’s Disease Alzheimer’s Drug
`Discovery Foundation 13-2471R2. Kador, P.F PI. 10/1/11 – 9/30/12.
`
`FAMY CARE - EXHIBIT 1032-0009
`
`

`
`Kador, Ph.D.
`
`10
`
`
`11. Evaluating Optixcare EH and Optixcare Hyaluronic Acid in Animal Models. Therapeutic Vision, Inc. contract
`with Aventix Animal Health 2/1/13-7/1/13.
`
`
`12. FDA MUMS Designation for KinostatTM to Therapeutic Vision, Inc. Waives all FDA user fees as well as
`provides 7 year exclusive license to sell KinostatTM in the US
`
`
`13. Using Molecular Attributes to Predict Ocular Drug Distribution 1R21EY023679-01A1 Kador, P. (P.I.) 4/1/14-
`3/30/16.
`
`
`14. Evaluating the mechanism of cataract formation in the rat lens. Agency: Therapeutic Vision Inc. sponsored by
`Vertex Pharmaceutical Company 1/2/2014.
`
`
`15. Treatment of Traumatic Retinal Damage With Multifunctional Antioxidants. PI Fliesler, S, University of
`Buffalo Veterans Hospital. DOD , P. Kador Contract
`16. Treatment of Canine Diabetic Cataracts, Therapeutic Vision Inc. 2 R44 EY018013-2b 9/1/15 8/31/2017
`Wyman (PI) P Kador contract
`17. Nebraska Small Business Innovation Research Initiative (SBIR) Matching Grant P. Kador
`
`18. UNMC Regenerative Medicine Pilot Grant for periodontal bine loss. 9/1/2014-12/1/2016.
`
`BIBLIOGRAPHY
`
`1. Miller, D.D., Merritt, W.V.P., Kador, P.F. and Feller, D.R.: Synthesis and biological actions of fragmented
`derivatives of tetrahydroisoquinolines. J. Med. Chem. 18: 99-102, 1975. PMCID: 1109581
`
`2. Miller, D.D., Kador, P.F., Venkatraman, R. and Feller, D.R.: Synthesis and biological evaluation of
`fragmented derivatives of tetrahydroisoquinolines 3. Trimetoquinol studies. J. Med. Chem. 19: 763-766,
`1976. PMCID: 950642
`
`3. Kador, P.F., Venkatraman, R., Feller, D.R. and Miller, D.D.: Synthesis and biological evaluation of a
`tetrahydroisoquinoline derivative possessing selective beta2-adrenergic agonist activity. J. Med. Chem. 20:
`891-894, 1977. PMCID: 17750
`
`4. Kador, P.F. and Kinoshita, J.H.: Phospholipid effects on the rat lens transport systems. Exp. Eye Res. 26:
`657-665, 1978. PMCID: 680023
`
`5. Kador, P.F. and Sharpless, N.E.: Structure-activity studies of aldose reductase inhibitors containing the 4-
`oxo-4H chromen ring system. Biophys. Chem. 8: 81-85, 1978. PMCID: 417745
`
`6. Kador, P.F., Merola, L.O. and Kinoshita, J.H.: Differences in the susceptibility of various aldose reductases
`to inhibition. Doc. Ophthalmol. Proc. Series 18: 117-124, 1979.
`
`7. Kador, P.F., Zigler, J.S. and Kinoshita, J.H.: Alterations of lens protein synthesis in galactosemic rats. Invest.
`Ophthalmol. Vis. Sci. 18: 696-702. PMCID: 6773903
`
`8. Kinoshita, J.H., Fukushi, S., Kador, P. and Merola, L.O.: Aldose reductase in diabetic complications of the
`eye. Metabolism 28: 462-469, 1979. PMCID: 45423
`
`9. Kador, P.F., Jernigan, H.M., Jr. and Kinoshita, J.H.: Accumulation and incorporation of radiolabeled choline
`into cultured rabbit lenses: Evidence for a choline transport system. Exp. Eye Res. 30: 1-12, 1980. PMCID:
`7363961
`
`
`
`FAMY CARE - EXHIBIT 1032-0010
`
`

`
`Kador, Ph.D.
`
`11
`
`
`16.
`
`10 Kador, P.F., Fukui, H.N., Fukushi, S., Jernigan, H.M. and Kinoshita, J.H. : Philly mouse: a new model of
`hereditary cataract. Exp. Eye Res. 30: 59-68, 1980. PMCID: 7363969
`
`Piatigorsky, J., Kador, P.F. and Kinoshita, J